Abstract: The disclosure relates to a method for treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and a second agent in a therapeutically effective amount. Preferably, the first agent comprises an EZH2 inhibitor, e.g., tazemetostat or a pharmaceutically acceptable salt thereof. In certain embodiments, the methods of the disclosure are used to treat breast cancer, ovarian cancer, or both.

Abstract: A topical composition for treating genital herpes includes dimethyl sulfoxide (DMSO), a diluent, and a quaternary ammonium compound. The topical composition may further contain a cannabinoid component, such as CBD, and/or a terpene and/or an essential oil. The topical composition may be in the form of a two-component composition in which a first topical composition includes dimethyl sulfoxide (DMSO), a diluent, and a quaternary ammonium compound and the second topical composition includes dimethyl sulfoxide (DMSO), a diluent, and a cannabinoid component.

Abstract: Treatments for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof. The treatments includes administration of compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.

Abstract: The present application includes a transdermal base formulation useful for example, for the transdermal delivery of active pharmaceutical ingredients along with a process for preparation thereof. In particular, the transdermal base formulation comprises: (a) an aqueous phase comprising water and at least one emulsion stabilizer; (b) an oil phase comprising at least one emulsifier, at least one emulsion stabilizer, at least one emollient comprising at least one flavonoid, at least one other emollient, and a terpene-rich natural butter; (c) an external phase comprising at least one terpene-rich extract or oil, at least one penetration enhancer and a phospholipid-complexed flavonoid; and optionally (d) at least one preservative phase.

Abstract: The invention is based on the discovery that rho kinase inhibitors, particularly fasudil can be used to treat agitation/anxiety in dementia patients, particularly Alzheimer's disease patients. Fasudil treatment of Alzheimer's patients resulted in improvements in agitation that are orders of magnitude to that observed with other potential therapeutic agents.

Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(IR,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.

Abstract: Provided herein are formulations effective for and methods of treating or preventing a neurodegenerative disorder in a subject in need thereof that can include administering an amount of an aPKC inhibitor to a subject in need thereof.

Abstract: This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4?-(((((2,2?-dichloro-[1,1?-biphenyl]-3,3?-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.

Abstract: The disclosure is directed to formulations comprising cannabinoids. More particularly, the cannabinoid formulations can be designed to align with an individual's genotype based on a defined list of polymorphisms.

Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

Abstract: The present invention relates to a novel cannabinoid oral pharmaceutical dosage form, based on a Type IV or Type IV-like formulation, as classified using the Lipid Formulation Classification System. The formulation is contained in a container. By Type IV-like, it is meant that the formulation comprises no oil, for example no triglycerides or mixed glycerides.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.

Abstract: Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compounds disclosed herein to a patient in need thereof that inhibit or slow one or more signs or symptoms of such conditions.

Abstract: Described herein are therapeutic pH responsive compositions comprising a block copolymer and a therapeutic agent useful for the treatment of cancer.

Abstract: The present invention describes a method of preventing, ameliorating and/or treating disorders or diseases associated with the integrated stress response (ISR) involving the p-eIF2? pathway arising from various cellular stresses such as oxidative stress, hypoxia and ER stress, chronic or prolonged bio-mechanical stress. In one embodiment, the present invention provides a method which prevents or alleviates aberrant cell differentiation that is caused by the activation of the integrated stress response and thereby prevents or alleviates conditions, disorders or diseases resulting therefrom. In one embodiment, ISR-associated diseases subject to the present invention include but are not limited to skeletal disorders including disc degeneration, MCDS and other skeletal dysplasias, cancers, inflammatory diseases, diabetes, fibrosis, obesity and neurodegenerative diseases.

Abstract: The present disclosure is directed to methods for the treatment of inflammation or pain, particularly methods using compositions containing a compound of formula (I).

Abstract: The present invention provides methods for inducing or enhancing rapid and significant dilation of a subject's pupils. In certain embodiments, the method comprises upregulating the alpha-1 receptors in the eye of the subject, thereby increasing sensitivity to alpha-1 agonists. In other embodiments, such upregulation is achieved through administration of at least one compound selected from the group consisting of alpha-2 selective agonists and beta adrenoreceptor antagonists for a period of time prior to the intended time of dilation. After inducing the upregulation of alpha-1 receptors through the administration of at least one compound selected from the group consisting of alpha-2 selective agonists and beta adrenoreceptor antagonists, alpha-1 agonists can be administered to induce or enhance rapid and strong pupil dilation.

Abstract: Chemical compounds/compositions, methods of synthesis, and methods of use are provided. The compounds/compositions are directed toward thyrointegrin antagonists directly conjugated to a polymer. The compounds/compositions may further comprise an additional substituent also conjugated to the polymer. The compounds/compositions may demonstrate antiangiogenic effect and efficacy against conditions, particularly cancers.

Abstract: Methods of treating cancer related conditions using anamorelin are described.